

## [Midazolam](#)

Essential medicine status

Section:

[5. Medicines for neurological disorders](#) [5.1. Medicines for central nervous system disorders](#) [5.1.1. Antiseizure medicines](#)

ATC codes: [N05CD08](#)

EMLc

Indication

Status epilepticus ICD11 code: [8A66](#)

INN

Midazolam

Medicine type

Chemical agent

List type

Core

Additional notes

Midazolam injection may be used for buccal administration when solution for oromucosal administration is not available.

Formulations

**Parenteral > General injections > unspecified:** 1 mg per mL in 5 mL vial (for buccal administration) ; 5 mg per mL in 1 mL vial (for buccal administration) ; 5 mg per mL in 3 mL vial (for buccal administration)

**Local > Buccal > Solution:** 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.75 mL pre-filled syringe ; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Midazolam](#)

[DrugBank](#)

[Midazolam](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended amendments to the listing for midazolam for status epilepticus on the EML and EMLc to better describe the available dosage forms.